98%
921
2 minutes
20
Introduction: Oral finasteride and topical minoxidil are long-standing androgenetic alopecia (AGA) treatments; topical finasteride is a more recent medicine. Few studies have compared their therapeutic effects in postmenopausal women. We compared the therapeutic impact of topical finasteride (1-4 sprays of 0.25% topical finasteride solution daily for 12 months), oral finasteride (2.5 mg oral finasteride once daily for 12 months), and topical minoxidil (1 mL of topical minoxidil 5% twice daily for 12 months) in postmenopausal women with AGA.
Methods: We conducted Bayesian network meta-analyses of individual patient-level data insofar as four clinically relevant endpoints, namely, 12-month change in (1) total hair density, (2) hair diameter, (3) clinical photographs, and (4) patients' opinion of efficacy. Data were obtained through medical charts. Regimens' surface under the cumulative ranking distribution (SUCRA) values and relative effects - as per odds ratios - were computed.
Results: As per SUCRA, the most and least effective regimens - across the four outcomes - were oral finasteride, and topical finasteride, respectively; however, no significant statistical differences were found (i.e., 0.05).
Conclusion: Oral finasteride is ranked more effective than the topical forms of minoxidil and finasteride; however, more studies are needed to confirm this result.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299975 | PMC |
http://dx.doi.org/10.1159/000538621 | DOI Listing |
J Eur Acad Dermatol Venereol
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management.
Objective: To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.
Cureus
August 2025
Medical Affairs Department, Shilpa Medicare Limited, Nacharam Unit, Hyderabad, IND.
Introduction Oral dutasteride has demonstrated superiority over finasteride in treating androgenetic alopecia (AGA). We have developed a novel topical dutasteride formulation, which has shown promising efficacy, safety, and tolerability in preclinical studies. The present study objective is to compare the efficacy and safety of dutasteride topical solutions (0.
View Article and Find Full Text PDFJ Cosmet Dermatol
September 2025
Medical Department, Cantabria Labs Difa Cooper, Milano, Italy.
Background: Minoxidil and finasteride are currently the only FDA-approved pharmacological treatments for androgenic alopecia (AGA) and female androgenic alopecia (FAGA). However, substantial improvement is observed in no more than 20% of patients in the medium term. To enhance clinical responses, nonpharmacological dietary supplementation is often utilized.
View Article and Find Full Text PDFInt J Pharm
October 2025
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016 Liaoning, PR China. Electronic address:
The core pathogenesis of androgenetic alopecia (AGA) involves abnormal accumulation of dihydrotestosterone (DHT) within hair follicles. However, while existing oral formulations achieve DHT suppression, their delayed clinical efficacy (3-6 months for visible regrowth) fails to meet the need for early intervention. Additionally, the frequent dosing further compromises sustained DHT control through drug-level fluctuations and adherence challenges, enabling local regeneration.
View Article and Find Full Text PDFPlanta Med
August 2025
Faculty of Pharmacy, Integral University, Lucknow, India.
Alopecia, characterised by partial or complete hair loss, significantly affects the psychological and social well-being of individuals. Current FDA-approved treatments, such as topical minoxidil and oral finasteride, often present limitations, including skin irritation and suboptimal efficacy, compromising patient adherence. In recent years, natural compounds have garnered attention as potential alternatives, with carnosic acid emerging as a promising candidate due to its multifaceted biological activities.
View Article and Find Full Text PDF